SynthesisMovement disorders clinical practice2026
The Hidden Burden of Hemifacial Spasm: A Systematic Review of Non-Motor Symptoms.
Synthesis in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemifacial spasm (HFS) is a chronic neurological disorder characterized by involuntary contractions of facial muscles. Traditionally regarded as a motor condition, HFS encompasses a spectrum of non-motor symptoms that are often overlooked but significantly affect patients' quality of life.
objectivesThis systematic review aimed to synthesize current evidence on the prevalence and clinical relevance of non-motor manifestations in HFS.
methodsA systematic search was conducted across PubMed, Cochrane, and EMBASE databases up to June 29, 2025, following PRISMA guidelines. Eligible studies included cross-sectional, cohort, case-control, and case series designs reporting pain, psychiatric symptoms, or sleep disturbances in HFS. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal tools according to study design.
resultsTwenty-two studies met inclusion criteria. Headache was reported in varying frequencies, ranging from 24.2% to 60% of cases, and facial pain in 33.3%, both frequently improving after botulinum toxin (BoNT) therapy. Psychiatric comorbidities were prevalent, with depression and anxiety reported in 5.7% to 29% and 9.1% to 19.5% of patients, respectively. Sleep disorders, mainly insomnia, occurred up to three times more often in HFS patients than in controls. BoNT therapy demonstrated beneficial effects beyond motor control, reducing pain, anxiety, and depressive symptoms.
conclusionHFS is a multidimensional disorder with substantial non-motor burden. Recognition and management of pain, psychiatric, and sleep-related symptoms are essential to improving treatment outcomes and overall patient well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.